Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-PSMA designer T cells
- Development stage
- Phase 2
- Lead developer
- Baylor College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-PSMA Designer T Cells are genetically engineered autologous T lymphocytes that have been modified to express a chimeric antigen receptor (CAR) targeting prostate-specific membrane antigen (PSMA), a cell surface protein highly expressed on prostate cancer cells. These "designer" or CAR-T cells are designed to recognize and kill PSMA-expressing tumor cells by redirecting the patient's own immune system against the cancer. The approach involves isolating patient T-cells, engineering them ex vivo with an anti-PSMA CAR construct, expanding them, and then reinfusing them into the patient. This therapy is being investigated primarily for metastatic castration-resistant prostate cancer (mCRPC) and has shown targeted cytotoxicity in preclinical models as well as early-phase clinical trials[1][2][3][4]. The mechanism of action is direct cytolytic activity against PSMA-positive tumor cells via engineered recognition.
- Other names
- anti-prostate specific membrane antigen designer T cellsPSMA CAR-T cellsanti-PSMA CAR-T cells
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on anti-PSMA designer T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-PSMA designer T cells.